The Effects of Beta Secretes on Alzheimer's Disease

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Clinical trials of these drugs all flocked and interested in them dried up until they got a second chance. None of the drugs had shown benefit, and worse, many had toxic side effects including worsened cognition. The goal was to help the field understand more about the disease-related biologies targeted by these investigational drugs. One such modulator, a compound developed in an academic collaboration, will be tested in an early clinical trial this year.

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.

Now, researchers are looking to drug combinations, vaccines and gene therapy to tackle different stages of the disease, as they forge the next generation of treatments for the condition.

This is an audio version of our Feature: Conquering Alzheimer’s: a look at the therapies of the future

Hosted on Acast. See acast.com/privacy for more information.